| 4.05 -0.04 (-0.98%) | 01-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.98 |
1-year : | 5.51 |
| Resists | First : | 4.26 |
Second : | 4.71 |
| Pivot price | 4.2  |
|||
| Supports | First : | 3.52 | Second : | 2.93 |
| MAs | MA(5) : | 4.2 |
MA(20) : | 4.17 |
| MA(100) : | 6.33 |
MA(250) : | 12.44 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 31.6 |
D(3) : | 39.8 |
| RSI | RSI(14): 43.6 |
|||
| 52-week | High : | 29.45 | Low : | 3.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ QLGN ] has closed above bottom band by 27.5%. Bollinger Bands are 67.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 40 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.14 - 4.16 | 4.16 - 4.19 |
| Low: | 3.98 - 4.01 | 4.01 - 4.04 |
| Close: | 4 - 4.05 | 4.05 - 4.1 |
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Thu, 05 Dec 2024
Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement - The Manila Times
Mon, 25 Nov 2024
Univest Securities, LLC Announces Successful Closing of - GlobeNewswire
Tue, 19 Nov 2024
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares - GlobeNewswire
Wed, 13 Nov 2024
QLGN Stock Touches 52-Week Low at $3.71 Amid Market Challenges - Investing.com
Tue, 22 Oct 2024
Qualigen Therapeutics faces Nasdaq delisting notice - Investing.com
Thu, 26 Sep 2024
Qualigen Therapeutics, Inc. Announces management changes. - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 242920 (%) |
| Held by Institutions | 3.7 (%) |
| Shares Short | 2 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -75.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.95e+007 |
| Qtrly Earnings Growth | 635 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | 1.35 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.03 |
| Dividend | 0 |
| Forward Dividend | 15590 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|